A headline links CME Group’s record third-quarter revenue to a valuation estimate that puts the stock 16% above fair value.
CME Group’s October 29 headline reports record Q3 revenue and says the shares may be 16% above fair value. But the supplied information doesn’t include the revenue figure, earnings details, or the method behind the estimate, so there isn’t enough detail to assess either claim.
Investor takeaway: The headline points to record Q3 revenue and a 16% above-fair-value estimate. The revenue amount and valuation method aren’t provided.
CME Group Inc
CME.US
CME.US
CME Group Inc
WealthAwesomeMarket cap
$106.10B
P/E
24.3x
Div. yield
1.75%
Div. / share
$5.15
52W high
$318.32
52W low
$217.29
1W change
-3.12%
Beta
0.27
Analyst Price Targets
Based on 17 analysts covering CME · as of Oct 28, 2026
Wall Street analysts forecast CME stock price to rise 7.0% over the next 12 months.
Consensus
Buy3.59 / 5.00
Avg. Target
C$317.06
+7.0% Upside
Previously C$316.00 on Oct 26, 2026
Current Price
C$296.42
Last close
Analyst Breakdown (17 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CME's historical volatility
30-Day Vol
26.5%
Annualized
90-Day Vol
25.6%
Annualized
Trend (90d)
+49.4%
Annualized drift
90d Mean
C$353.58
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$314.37 | C$286.90 – C$344.46 |
| 60 trading days | C$333.40 | C$292.96 – C$379.41 |
| 90 trading days | C$353.58 | C$301.80 – C$414.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
16% above fair value
The headline gives that estimate but doesn’t explain how fair value was calculated.
Bull case
The headline reports record Q3 revenue. The supplied company data also show a 63.5% profit margin and 16.1% return on equity.
Bear case
The 16% above-fair-value estimate raises a valuation concern, but the information provided doesn’t include the estimate’s basis or details of Q3 revenue.
The headline pairs record revenue with a valuation warning
CME Group’s October 29 headline reports record Q3 revenue and suggests the stock could be 16% above fair value. The supplied information doesn’t include the revenue total, year-over-year comparison, earnings per share, or quarterly filing details. It also doesn’t identify who made the fair-value estimate or explain the assumptions behind it. The headline gives a broad picture, but the figures needed to verify the revenue record and assess the valuation claim are missing. CME Group is a financial company, but the supplied facts don’t say which business lines drove the quarter.
The supplied share data show a recent monthly gain
CME closed at US$296.42, up 0.81% for the day and 12.61% over the month. Its one-week return was down 3.12%. The shares were up 13.66% year to date and stood at 78% of their 52-week range of US$217.29 to US$318.32. Latest reported volume was 5,208 shares, compared with a 20-day average of 2,099,114; the supplied volume comparison is 1.04x. These figures describe the stock’s performance but don’t show that the Q3 headline caused the price movement. CME’s supplied valuation data include a P/E ratio of 24.2967 and a market capitalization of about US$106.1 billion. See the CME Group stock page for more company information.
Revenue details and valuation assumptions remain unknown
Investors will need the Q3 results to see the revenue amount and how it compares with earlier periods. The supplied facts don’t say when those details will be available or include a filing link, so there’s no specific next date to point to. The basis for the 16% fair-value estimate is also unclear. The headline doesn’t identify its inputs or say whether it comes from a particular analyst or valuation model. The supplied analyst target is US$317.06, but that figure is separate from the headline’s fair-value estimate and doesn’t explain how it was calculated. Follow CME’s stock information for company results and valuation details as they become available.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
